AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro continues to gain market share despite being available in the EU only on a ‘Named Patient’ basis. Trials for full approval as a biological have progressed well in the EU, with the first patient recruited in the pivotal birch pollen allergy vaccine Phase III trial. US trials are back on-track with a new safety trial underway. Investment in marketing infrastructure over the last two years is bearing fruit with strong underlying sales growth in a flat market, improving market share by an estimated two percentage points.